1.Rogers, LS, Glatz, AC, Ravishankar, C, et al. 18 years of the Fontan operation at a single institution: results from 771 consecutive patients. J Am Coll Cardiol 2012; 60: 1018–1025.
2.Fontan, F, Baudet, E. Surgical repair of tricuspid atresia. Thorax 1971; 26: 240–248.
3.de Leval, MR, Deanfield, JE. Four decades of Fontan palliation. Nat Rev Cardiol 2010; 7: 520–527.
4.Gewillig, M, Brown, SC, Eyskens, B, et al. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg 2010; 10: 428–433.
5.de Leval, MR, Dubini, G, Migliavacca, F, et al. Use of computational fluid dynamics in the design of surgical procedures: application to the study of competitive flows in cavo-pulmonary connections. J Thorac Cardiovasc Surg 1996; 111: 502–513.
6.Penny, DJ, Redington, AN. Diastolic ventricular function after the Fontan operation. Am J Cardiol 1992; 69: 974–975.
7.Ho, PK, Lai, CT, Wong, SJ, Cheung, YF. Three-dimensional mechanical dyssynchrony and myocardial deformation of the left ventricle in patients with tricuspid atresia after Fontan procedure. J Am Soc Echocardiogr 2012; 25: 393–400.
8.Henaine, R, Vergnat, M, Bacha, EA, et al. Effects of lack of pulsatility on pulmonary endothelial function in the Fontan circulation. J Thorac Cardiovasc Surg 2013; 146: 522–529.
9.Rychik, J, Fogel, MA, Donofrio, MT, et al. Comparison of patterns of pulmonary venous blood flow in the functional single ventricle heart after operative aortopulmonary shunt versus superior cavopulmonary shunt. Am J Cardiol 1997; 80: 922–926.
10.Steding-Ehrenborg, K, Carlsson, M, Stephensen, S, Arheden, H. Atrial aspiration from pulmonary and caval veins is caused by ventricular contraction and secures 70% of the total stroke volume independent of resting heart rate and heart size. Clin Physiol Funct Imaging 2013; 33: 233–240.
11.Gewillig, M, Brown, SC, Heying, R, et al. Volume load paradox while preparing for the Fontan: not too much for the ventricle, not too little for the lungs. Interact Cardiovasc Thorac Surg 2010; 10: 262–265.
12.Rychik, J. Forty years of the Fontan operation: a failed strategy. Seminars in thoracic and cardiovascular surgery Pediatr Cardiac Surg Ann 2010; 13: 96–100.
13.Lemmer, JH, Coran, AG, Behrendt, DM, Heidelberger, KP, Stern, AM. Liver fibrosis (cardiac cirrhosis) five years after modified Fontan operation for tricuspid atresia. J Thorac Cardiovasc Surg 1983; 86: 757–760.
14.Schwartz, MC, Sullivan, L, Cohen, MS, et al. Hepatic pathology may develop before the Fontan operation in children with functional single ventricle: an autopsy study. J Thorac Cardiovasc Surg 2012; 143: 904–909.
15.Ghaferi, AA, Hutchins, GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg 2005; 129: 1348–1352.
16.Schwartz, MC, Sullivan, LM, Glatz, AC, et al. Portal and sinusoidal fibrosis are common on liver biopsy after Fontan surgery. Pediatr Cardiol 2013; 34: 135–142.
17.Kendall, TJ, Stedman, B, Hacking, N, et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol 2008; 61: 504–508.
18.Kiesewetter, CH, Sheron, N, Vettukattill, JJ, et al. Hepatic changes in the failing Fontan circulation. Heart 2007; 93: 579–584.
19.Bryant, T, Ahmad, Z, Millward-Sadler, H, et al. Arterialised hepatic nodules in the Fontan circulation: hepatico-cardiac interactions. Int J Cardiol 2011; 151: 268–272.
20.Friedrich-Rust, M, Koch, C, Rentzsch, A, et al. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. J Thorac Cardiovasc Surg 2008; 135: 560–567.
21.Baek, JS, Bae, EJ, Ko, JS, et al. Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. Heart 2010; 96: 1750–1755.
22.Ferraioli, G, Tinelli, C, Dal Bello, B, et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012; 56: 2125–2133.
23.Rychik, J, Veldtman, G, Rand, E, et al. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol 2012; 33: 1001–1012.
24.Mertens, L, Hagler, DJ, Sauer, U, Somerville, J, Gewillig, M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998; 115: 1063–1073.
25.Meadows, J, Jenkins, K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young 2011; 21: 363–377.
26.Thorne, SA, Hooper, J, Kemp, M, Somerville, J. Gastro-intestinal protein loss in late survivors of Fontan surgery and other congenital heart disease. Eur Heart J 1998; 19: 514–520.
27.Rychik, J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis 2007; 2: 288–300.
28.Rychik, J, Gui-Yang, S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 2002; 90: 672–674.
29.Uzun, O, Wong, JK, Bhole, V, Stumper, O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006; 82: e39–e40.
30.Cohen, MI, Rhodes, LA, Wernovsky, G, Gaynor, JW, Spray, TL, Rychik, J. Atrial pacing: an alternative treatment for protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 2001; 121: 582–583.
31.Jacobs, ML, Rychik, J, Byrum, CJ, Norwood, WI Jr. Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 1996; 61: 206–208.
32.Rychik, J, Rome, JJ, Jacobs, ML. Late surgical fenestration for complications after the Fontan operation. Circulation 1997; 96: 33–36.
33.Bernstein, D, Naftel, D, Chin, C, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation 2006; 114: 273–280.
34.Ostrow, AM, Freeze, H, Rychik, J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 2006; 82: 695–700.
35.Rychik, J, Piccoli, DA, Barber, G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 1991; 68: 819–821.
36.Zellers, TM, Brown, K. Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol 1996; 17: 115–117.
37.Bode, L, Eklund, EA, Murch, S, Freeze, HH. Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy. Am J Physiol Gastrointest Liver Physiol 2005; 288: G1015–G1023.
38.Bode, L, Murch, S, Freeze, HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem 2006; 281: 7809–7815.
39.Amadi, B, Fagbemi, AO, Kelly, P, et al. Reduced production of sulfated glycosaminoglycans occurs in Zambian children with kwashiorkor but not marasmus. Am J Clin Nutr 2009; 89: 592–600.
40.Thacker, D, Patel, A, Dodds, K, Goldberg, DJ, Semeao, E, Rychik, J. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2010; 89: 837–842.
41.Turner, Z, Lanford, L, Webber, S. Oral budesonide as a therapy for protein-losing enteropathy in patients having undergone Fontan palliation. Congenit Heart Dis 2012; 7: 24–30.
42.Rychik, J. Invited commentary. Ann Thorac Surg 2011; 92: 1456.
43.John, AS, Driscoll, DJ, Warnes, CA, Phillips, SD, Cetta, F. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2011; 92: 1451–1456.
44.Schumacher, KR, Cools, M, Goldstein, BH, et al. Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients. Pediatr Cardiol 2011; 32: 966–971.
45.Mertens, L, Dumoulin, M, Gewillig, M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. Br Heart J 1994; 72: 591–592.
46.Kanter, KR, Mahle, WT, Vincent, RN, Berg, AM, Kogon, BE, Kirshbom, PM. Heart transplantation in children with a Fontan procedure. Ann Thorac Surg 2011; 91: 823–829; discussion 9–30.
47.Larue, M, Gossett, JG, Stewart, RD, Backer, CL, Mavroudis, C, Jacobs, ML. Plastic bronchitis in patients with Fontan physiology: review of the literature and preliminary experience with Fontan conversion and cardiac transplantation. World J Pediatr Congenit Heart Surg 2012; 3: 364–372.
48.Stiller, B, Riedel, F, Paul, K, van Landeghem, FK. Plastic bronchitis in children with Fontan palliation: analogue to protein-losing enteropathy? Pediatr Cardiol 2002; 23: 90–94.
49.Racz, J, Mane, G, Ford, M, et al. Immunophenotyping and protein profiling of Fontan-associated plastic bronchitis airway casts. Ann Am Thorac Soc 2013; 10: 98–107.
50.Caruthers, RL, Kempa, M, Loo, A, et al. Demographic characteristics and estimated prevalence of Fontan-associated plastic bronchitis. Pediatr Cardiol 2013; 34: 256–261.
51.Wilson, J, Russell, J, Williams, W, Benson, L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. Pediatr Cardiol 2005; 26: 717–719.
52.Chaudhari, M, Stumper, O. Plastic bronchitis after Fontan operation: treatment with stent fenestration of the Fontan circuit. Heart 2004; 90: 801.
53.Barber, BJ, Burch, GH, Tripple, D, Balaji, S. Resolution of plastic bronchitis with atrial pacing in a patient with Fontan physiology. Pediatr Cardiol 2004; 25: 73–76.
54.Laubisch, JE, Green, DM, Mogayzel, PJ, Reid Thompson, W. Treatment of plastic bronchitis by orthotopic heart transplantation. Pediatr Cardiol 2011; 32: 1193–1195.
55.ElMallah, MK, Prabhakaran, S, Chesrown, SE. Plastic bronchitis: resolution after heart transplantation. Pediatr Pulmonol 2011; 46: 824–825.
56.Haseyama, K, Satomi, G, Yasukochi, S, Matsui, H, Harada, Y, Uchita, S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2006; 132: 1232–1233.
57.Apostolopoulou, SC, Papagiannis, J, Rammos, S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005; 24: 1174–1176.
58.Costello, JM, Steinhorn, D, McColley, S, Gerber, ME, Kumar, SP. Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics 2002; 109: e67.
59.Wakeham, MK, Van Bergen, AH, Torero, LE, Akhter, J. Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient. Pediatr Crit Care Med 2005; 6: 76–78.
60.Do, TB, Chu, JM, Berdjis, F, Anas, NG. Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. Pediatr Cardiol 2009; 30: 352–355.
61.Lubcke, NL, Nussbaum, VM, Schroth, M. Use of aerosolized tissue plasminogen activator in the treatment of plastic bronchitis. Ann Pharmacother 2013; 47: e13.
62.Parikh, K, Witte, MH, Samson, R, et al. Successful treatment of plastic bronchitis with low fat diet and subsequent thoracic duct ligation in child with fontan physiology. Lymphology 2012; 45: 47–52.
63.Shah, SS, Drinkwater, DC, Christian, KG. Plastic bronchitis: is thoracic duct ligation a real surgical option? Ann Thorac Surg 2006; 81: 2281–2283.
64.Ezmigna, DR, Morgan, WJ, Witte, MH, Brown, MA. Lymphoscintigraphy in plastic bronchitis, a pediatric case report. Pediatr Pulmonol 2013; 48: 515–518.